JPRN-UMIN000021143
Completed
未知
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndrome - Rituximab to refractory nephrotic syndrome
Fujita Health University School of Medicine, Department of Nephrology0 sites10 target enrollmentFebruary 23, 2016
ConditionsRefractory nephrotic syndrome
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Refractory nephrotic syndrome
- Sponsor
- Fujita Health University School of Medicine, Department of Nephrology
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Severe hypersensitivity to the component of rituximab or products derived from mouse protein. 2\. Positive serology for HBs antigen or HBv\-DNA 3\. Active infection
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10
Completed
Not Applicable
Rituximab therapy for refractory pemphigusJPRN-jRCTs031180405Funakoshi Takeru20
Recruiting
Not Applicable
Safety evaluation study about rituximab therapy for refractory pemphiguspemphigusJPRN-UMIN000026004Keio University, School of Medicine20
Active, not recruiting
Phase 1
Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitisEUCTR2018-000637-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)106
Completed
Phase 2
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27